ArticleFrontiers in immunology2026
Human CD4
Niharika M Patankar, Kelsey A Smith, Nidus Jacobsen, Nikhila S Bharadwaj, Jenny E Gumperz
Abstract read
In one paragraphArticle in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
5 authors.
Niharika M PatankarDepartment of Medical Microbiology and Immunology, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
Kelsey A SmithDepartment of Medical Microbiology and Immunology, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
Nidus JacobsenDepartment of Medical Microbiology and Immunology, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
Nikhila S BharadwajDepartment of Medical Microbiology and Immunology, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
Jenny E GumperzDepartment of Medical Microbiology and Immunology, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
Funding
UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6McGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine75N93022D00005 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI HASSELL, THOMAS · 2022 to 2025
$8.0MTask Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1MRole of Epstein-Barr virus LMP2A protein in maintaining oncogenic IgM signaling in EBV+ B cell lymphomasU01CA275247 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI ERIC C JOHANNSEN · 2022 to 2026
$2.2MMechanisms of iNKT cell anti-viral adjuvancyR01AI136500 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI GUMPERZ, JENNY E. · 2018 to 2022
$1.9MAutomated Tissue MicroarrayerS10OD023526 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI MATKOWSKYJ, KRISTINA A. · 2018 to 2018
$184kNCI NIH HHS P30 CA014520NCI NIH HHS U01 CA275247NHLBI NIH HHS 75N92020D00005NIAID NIH HHS 75N93022D00005NIAID NIH HHS R01 AI136500NIDA NIH HHS 75N95020D00005NIH HHS 75N93023D00005NIH HHS 75N99020D00005NIH HHS S10 OD023526
6 · The paper itselfAbstract
Invariant natural killer T (iNKT) cells are promising candidates for allogeneic cellular immunotherapy, but the metabolic pathways that support their effector function in nutrient-limited tumor microenvironments remain poorly defined. Human iNKT cells segregate into CD4
Indexed as
CD4-Positive T-LymphocytesGlycogenInterferon-gammaNatural Killer T-CellsAnimalsGlucoseGlycolysisHumansMetabolic ReprogrammingMiceTumor MicroenvironmentGlucoseGlycogenInterferon-gammaglucose independenceglycogen storesinterferon-gamma (IFN-g)invariant natural killer T (iNKT) cellmetabolic resilienceoxidative phosphorylation (OXPHOS)spare respiratory capacity (SRC)
Identifiers
PMID42676652
PMCPMC13527001
What OpenQuestion holds
Textmetadata
Read underepoch 390